CSF1R and pulmonary arterial hypertension: Seralutinib acts as a kinase inhibitor targeting platelet-derived growth factor receptor (PDGFR)/colony-stimulating factor 1 receptor (CSF1R)/c-KIT, designed to be administered by inhalation for PAH treatment.